reports
- David Nierengarten
- Dennis Pak
- Martin Fan
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and...
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Positive Clinical Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Confirm Tolerability Profile, Show Strong Efficacy Signal, and Validate ITK as Therapeutic Target - - Advanced Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) into Phase 2 Trial in Atopic Dermatitis (AD); Patient Dosing Underway - - Initiated Dosing in Phase 1a/1b Clinical Program for Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAY...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
VRNS VARONIS SYSTEMS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
BKNG BOOKING HOLDINGS INC.
SMCI SUPER MICRO COMPUTER
FUBO INC.
U FUBOTV
NUVB UNITY SOFTWARE
STX NUVATION BIO INC (A)
SEAGATE TECHNOLOGY HLDGS PLC
- David Nierengarten
- Dennis Pak
- Martin Fan
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Lab...
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints - Primary Endpoint Analysis Confirms Favorable Tolerability Profile of ATI-2138 Without Certain Risks Associated with Other Agents in the Class - - Efficacy Results Show Comparable Outcomes to Approved Therapies with Potential for Improved Tolerability, Supporting Exploration of Higher Doses in Future Clinical Trials - - Pharmacodynamic Results Validate Therapeutic Potential...
Aclaris Therapeutics Announces Leadership Transition
Aclaris Therapeutics Announces Leadership Transition - Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, re...
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
- Wedbush Research
NVCR NOVOCURE LTD.
MNKD MANNKIND CORP.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ACRS ACLARIS THERAPEUTICS INC.
DHI D.R. HORTON INC.
BLDR BUILDERS FIRSTSOURCE INC.
ARGX ARGENX ADS
APLS APELLIS PHARMACEUTICALS
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
UFPI UFP INDUSTRIES INC.
JANX JANUX THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ACRS ACLARIS THERAPEUTICS INC.
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
SMCI SUPER MICRO COMPUTER
RZLT INC.
STX REZOLUTE
GFS SEAGATE TECHNOLOGY HLDGS PLC
TLX GLOBALFOUNDRIES INC
CBIO TELIX PHARMACEUTICALS LIMITED
CRESCENT BIOPHARMA INC.
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Inde...
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025. The annual Russell US Indexes reconstit...
- Wedbush Research
MNKD MANNKIND CORP.
GOOGL ALPHABET INC. CLASS A
BCRX BIOCRYST PHARMACEUTICALS INC.
ACRS ACLARIS THERAPEUTICS INC.
PTGX PROTAGONIST THERAPEUTICS
ZG ZILLOW GROUP INC. CLASS A
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
COGT COGENT BIOSCIENCES INC
RKT ROCKET COMPANIES
APGE APOGEE THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammatio...
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT. A live and archived webcast of the presentation will be accessible ...
- Wedbush Research
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispe...
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 - Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company’s potential best-in-class investigational bi...
- David Nierengarten
- Dennis Pak
- Martin Fan
- David Nierengarten
- Dennis Pak
- Dylan Shindler
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.